Sequel Med Tech to Integrate Twiist Automated Insulin Delivery System with Abbott's Future Dual Glucose-Ketone Sensor

Published: 2025-05-22 16:57:24 ET ABT

Published on 05/22/2025 at 16:57

Sequel Med Tech, LLC announced a commercial development agreement for future integration of Sequel's twiist Automated Insulin Delivery (AID) System powered by Tidepool, with Abbott's glucose-ketone sensor, currently under development. The agreement aims to improve outcomes for people with type 1 diabetes by adding ketone sensing capabilities to a Libre glucose sensor in combination with the twiist AID System to enable earlier detection of rising ketones. Regular measurement of ketones has been shown to reduce the risk of diabetic ketoacidosis in people living with type 1 diabetes2.

Sequel's expanded integration with Abbott's sensor underscores the company's commitment to delivering more choice, flexibility and confidence to people managing type 1 diabetes. People living with type 1 diabetes who use twiist will be able to select from compatible CGM systems, including Abbott's FreeStyle Libre®? 3 Plus sensor and, in the future, the Senseonics Eversense 365 to best suit their individual needs for managing diabetes.

Abbott's glucose-ketone sensors will be added in the future once the product is cleared for use and available in the U.S. The twiist AID System features proprietary iiSure?? Technology, which directly measures the volume of insulin delivered with each micro-dose. It includes four checkpoints that measure the insulin quantity delivered and enables the system to alert users to blockages up to nine times faster than competing AID systems3.

Cleared for people ages six and up with type 1 diabetes, the twiist AID system offers the capability and flexibility to address each person's individual dosing needs. The twiist Loop algorithm, based on Tidepool Loop, an intuitive and smart technology designed by people with diabetes for people with diabetes, allows the system to automatically adjust basal insulin delivery based on real-time sensor readings and predicted glucose levels.